TLX-591 companion diagnostic (Telix Pharmaceuticals)
Tier C — Watch / tradeTLX-591 companion diagnostic (Telix Pharmaceuticals)
Targets：PSMA
Brand：ILLUCCIX, Gallium Ga 68 Psma-11, Locametz, Illuccix
Indications (approved)：Prostate cancer, Diagnostic agent
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)828549-1-a | - | Resin bound (2S)-6-amino-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid |
| (II)828549-1-a | 88574-06-5 | 6-([[(9H-Fluoren-9-yl)methoxy]carbonyl]amino)hexanoic acid |
| (III)828549-1-a | - | Resin bound (2S)-6-[(6-Aminohexanoyl)amino]-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid |
| (IV)828549-1-a | 1366302-51-3 | (2S)-6-[(6-Aminohexanoyl)amino]-2-([[(2S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl]carbamoyl]amino)hexanoic acid |
| (V)828549-1-a,(V)828549-1-b | 1309876-75-2 | 3-(3-[[(Carboxymethyl)[2-[(carboxymethyl)([2-hydroxy-5-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]phenyl]methyl)amino]ethyl]amino]methyl]-4-hydroxyphenyl)propanoic acid |
| (VI)828549-1-a | 1366302-52-4 | N-[[(1S)-1-Carboxy-5-([6-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]hexanoyl]amino)pentyl]carbamoyl]-L-glutamic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| (V)828549-1-a,(V)828549-1-b | 1309876-75-2 | 3-(3-[[(Carboxymethyl)[2-[(carboxymethyl)([2-hydroxy-5-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]phenyl]methyl)amino]ethyl]amino]methyl]-4-hydroxyphenyl)propanoic acid |
| (VII)828549-1-b | 501-97-3 | 3-(4-Hydroxyphenyl)propionic acid |
| (VIII)828549-1-b | 5657-17-0 | 2,2'-(Ethane-1,2-diyldiazanediyl)diacetic acid |
| (IX) 828549-1-b | 143557-99-7 | 3,3'-(Ethane-1,2-diylbis[[(carboxymethyl)azanediyl]methylene(4-hydroxy-3,1-phenylene)])dipropanoic acid |
| (X)828549-1-b | - | 2,2'-[Ethane-1,2-diylbis([[5-(2-carboxyethyl)-2-oxidophenyl]methyl]azanediyl)]diacetate iron(3+) |
| (XI)828549-1-b | - | [[2-[[[5-(2-Carboxyethyl)-2-oxidophenyl]methyl](carboxylatomethyl)amino]ethyl]([2-oxido-5-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]phenyl]methyl)amino]acetate iron(3+) |
Frequently asked questions
What are the approved indications of TLX-591 companion diagnostic (Telix Pharmaceuticals)?
Approved indications include: Prostate cancer, Diagnostic agent.
When does the TLX-591 companion diagnostic (Telix Pharmaceuticals) patent expire?
No public expiry year is available for TLX-591 companion diagnostic (Telix Pharmaceuticals) yet; this page updates once verified.
How many synthesis routes are recorded for TLX-591 companion diagnostic (Telix Pharmaceuticals)?
2 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy TLX-591 companion diagnostic (Telix Pharmaceuticals) intermediates?
All intermediates in TLX-591 companion diagnostic (Telix Pharmaceuticals) routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for TLX-591 companion diagnostic (Telix Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27